Lineage Cell Therapeutics, Inc.
DE ˙ DB ˙ US53566P1093
1,01 € ↓ -0,04 (-3,63%)
2026-06-03
AKTIENPREIS
SecurityDE:BT3 / Lineage Cell Therapeutics, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership499,127 shares
Latest Disclosed Value $ 788,621
Northern Trust Corp reports 4.14% increase in ownership of BT3 / Lineage Cell Therapeutics, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 499,127 shares of Lineage Cell Therapeutics, Inc. (DE:BT3) valued at $628,900 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 479,273 shares of Lineage Cell Therapeutics, Inc.. This represents a change in shares of 4.14% during the quarter. The current value of the position is $504,118 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 499,127 19,854 4.14 789 -1.50 0.0000
2026-02-17 2025-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 479,273 35,921 8.10 800 6.81 0.0001
2025-11-14 2025-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 443,352 -67,110 -13.15 749 61.77 0.0001
2025-08-13 2025-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 510,462 -1,029,124 -66.84 463 -33.38 0.0001
2025-05-13 2025-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,539,586 265,094 20.80 695 8.59 0.0001
2025-02-14 2024-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,274,492 -81 -0.01 640 -44.49 0.0001
2024-11-13 2024-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,274,573 83,255 6.99 1,154 -2.95 0.0002
2024-08-14 2024-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,191,318 -41,228 -3.34 1,188 -34.87 0.0002
2024-05-14 2024-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,232,546 37,362 3.13 1,824 40.09 0.0003
2024-02-13 2023-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,195,184 -8,773 -0.73 1,303 -8.31 0.0002
2023-11-13 2023-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,203,957 100,825 9.14 1,421 -8.68 0.0003
2023-08-11 2023-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,103,132 866,049 365.29 1,555 338.03 0.0003
2023-05-15 2023-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 237,083 13,633 6.10 356 36.02 0.0001
2023-02-13 2022-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 223,450 0 0.00 261 3.57 0.0001
2022-11-14 2022-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 223,450 21,675 10.74 252 -21.00 0.0001
2022-08-12 2022-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 201,775 -829,034 -80.43 319 -79.90 0.0001
2022-05-13 2022-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,030,809 -50,115 -4.64 1,587 -40.07 0.0003
2022-02-08 2021-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,080,924 -416,703 -27.82 2,648 -29.84 0.0004
2021-11-15 2021-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,497,627 -131,122 -8.05 3,774 -18.68 0.0007
2021-08-13 2021-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,628,749 1,332,456 449.71 4,641 566.81 0.0008
2021-05-12 2021-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 296,293 34,264 13.08 696 50.98 0.0001
2021-02-11 2020-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 262,029 -7,027 -2.61 461 82.94 0.0001
2020-11-16 2020-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 269,056 25,921 10.66 252 19.43 0.0001
2020-08-14 2020-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 243,135 -1,039,421 -81.04 211 -80.13 0.0000
2020-05-14 2020-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,282,556 124,855 10.78 1,062 3.01 0.0003
2020-02-14 2019-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,157,701 -43,658 -3.63 1,031 -12.40 0.0002
2019-11-13 2019-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,201,359 -42,023 -3.38 1,177 -13.90 0.0003
2019-08-13 2019-06-30 13F BIOTIME COM 09066L105 1,243,382 11,067 0.90 1,367 -15.30 0.0003
2019-05-13 2019-03-31 13F BIOTIME COM 09066L105 1,232,315 238,762 24.03 1,614 77.95 0.0004
2019-02-12 2018-12-31 13F BIOTIME COM 09066L105 993,553 -3,890 -0.39 907 -61.31 0.0003
2018-11-14 2018-09-30 13F BIOTIME COM 09066L105 997,443 -18,783 -1.85 2,344 11.94 0.0006
2018-09-18 2018-06-30 13F/A-1 BIOTIME COM 09066L105 1,016,226 49,778 5.15 2,094 -19.46 0.0005
2018-08-14 2018-06-30 13F BIOTIME COM 09066L105 1,016,226 49,778 2,094
2018-05-09 2018-03-31 13F BIOTIME COM 09066L105 966,448 47,957 5.22 2,600 31.65 0.0007
2018-02-14 2017-12-31 13F BIOTIME COM 09066L105 918,491 50,878 5.86 1,975 -19.81 0.0005
2017-11-13 2017-09-30 13F BIOTIME COM 09066L105 867,613 541,593 166.12 2,463 139.82 0.0006
2017-08-11 2017-06-30 13F BIOTIME COM 09066L105 326,020 -562,850 -63.32 1,027 -66.51 0.0003
2017-05-12 2017-03-31 13F BIOTIME COM 09066L105 888,870 146,548 19.74 3,067 14.44 0.0009
2017-02-13 2016-12-31 13F BIOTIME COM 09066L105 742,322 29,018 4.07 2,680 -3.67 0.0008
2016-11-09 2016-09-30 13F BIOTIME COM 09066L105 713,304 13,178 1.88 2,782 52.27 0.0009
2016-08-12 2016-06-30 13F BIOTIME COM 09066L105 700,126 73,987 11.82 1,827 1.67 0.0006
2016-08-19 2016-03-31 13F/A-1 BIOTIME COM 09066L105 626,139 27,765 4.64 1,797 -26.74 0.0006
2016-05-13 2016-03-31 13F BIOTIME COM 09066L105 626,139 1,797
2016-02-12 2015-12-31 13F BIOTIME COM 09066L105 598,374 47,655 8.65 2,453 48.49 0.0008
2015-11-12 2015-09-30 13F BIOTIME COM 09066L105 550,719 26,150 4.99 1,652 -13.28 0.0006
2015-08-13 2015-06-30 13F BIOTIME COM 09066L105 524,569 -2,808 -0.53 1,905 -27.32 0.0013
2015-05-14 2015-03-31 13F BIOTIME COM 09066L105 527,377 510 0.10 2,621 33.38 0.0008
2015-02-12 2014-12-31 13F BIOTIME COM 09066L105 526,867 -13,756 -2.54 1,965 15.79 0.0006
2014-11-13 2014-09-30 13F BIOTIME COM 09066L105 540,623 99,756 22.63 1,697 26.17 0.0005
2014-08-14 2014-06-30 13F BIOTIME COM 09066L105 440,867 -19,412 -4.22 1,345 -11.22 0.0004
2014-05-14 2014-03-31 13F BIOTIME COM 09066L105 460,279 -35,555 -7.17 1,515 -15.13 0.0005
2014-02-21 2013-12-31 13F/A-1 BIOTIME COM 09066L105 495,834 7,948 1.63 1,785 -3.72 0.0006
2014-02-12 2013-12-31 13F BIOTIME COM 09066L105 495,834 1,785
2013-11-13 2013-09-30 13F BIOTIME COM 09066L105 487,886 43,431 9.77 1,854 5.34 0.0007
2013-08-09 2013-06-30 13F BIOTIME COM 09066L105 444,455 444,455 1,760 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.